Should TB Medications Be Continued on the Day of Surgery?
Yes, anti-tuberculosis medications should be continued on the day of surgery without interruption. There is no evidence-based rationale to skip TB drugs perioperatively, and maintaining therapeutic drug levels is critical to prevent treatment failure and drug resistance.
Rationale for Continuing TB Medications
The available evidence does not support withholding anti-TB drugs on the day of surgery. While the provided guidelines 1, 2 extensively detail treatment regimens, durations, and drug selection for drug-resistant TB, none recommend interrupting therapy for surgical procedures. This absence of any recommendation to skip doses is itself telling—if perioperative interruption were necessary or beneficial, major guidelines would address it explicitly.
Key Considerations for Perioperative TB Management
Preoperative Treatment Duration
- Patients with spinal TB can safely undergo surgery after 2-4 weeks of anti-TB treatment 3
- Both 2-week and 4-week preoperative treatment durations showed similar surgical outcomes (wound healing rates ~90-94%, bony fusion rates ~95-98%) 3
- Surgery should proceed when ESR and CRP are in a descending or stable period 4
Maintaining Drug Continuity
The principle of uninterrupted therapy is paramount because:
- Drug resistance develops when treatment is inadequate 5—even brief interruptions can create selective pressure
- TB drugs have specific pharmacokinetic profiles that require consistent dosing to maintain therapeutic levels 6
- Patients who are inadequately treated remain chronic carriers and can spread disease 7
Route of Administration Alternatives
If oral administration is impossible perioperatively 5:
- Intramuscular streptomycin and isoniazid can be used
- Intravenous quinolones are available
- Drugs can be crushed and administered via nasogastric tube or gastrostomy
- Switch back to oral therapy once oral intake resumes
Critical Pitfalls to Avoid
Do not skip TB medications based on unfounded concerns about:
- Anesthesia interactions—while drug interactions exist 8, they require dose adjustments, not omission
- Surgical complications—the evidence shows good surgical outcomes with continued therapy 3
- Gastrointestinal absorption issues—alternative routes exist if needed
The real risks lie in interrupting therapy:
- Development of drug resistance (primary MDR-TB incidence was 1.4% but acquired MDR-TB reached 14% in one surveillance study due to poor chemotherapy) 5
- Treatment failure requiring longer, more toxic regimens 1, 2
- Continued infectivity to healthcare workers and family 7
Practical Algorithm
- Continue all TB medications on the day of surgery using the patient's regular schedule
- If NPO status prevents oral intake: Use parenteral alternatives (IM streptomycin/isoniazid or IV fluoroquinolones) or nasogastric administration
- Resume oral medications as soon as oral intake is tolerated postoperatively
- Monitor for drug interactions with anesthetic agents and adjust doses if needed, but do not omit drugs 8
The evidence consistently supports maintaining anti-TB therapy throughout the perioperative period to ensure treatment success and prevent the catastrophic consequence of acquired drug resistance.